M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
OSI says Tarceva to be reviewed by FDA committee for use as first-line maintenance therapy in advanced NSCLC
16 November 2009 - US-based OSI Pharmaceuticals Inc (NASDAQ: OSIP) said today that FDA's Oncologic Drugs Advisory Committee (ODAC) will review the use of Tarceva (erlotinib) as a first-line maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) who have not progressed...If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search